GHK-Cu Dosage: Topical vs Injectable and What the Evidence Supports

GHK-Cu dosage is one of the most common questions about the copper peptide, and one of the least clearly answered. The honest starting point: GHK-Cu is not an FDA-approved drug, so there is no labeled dose, and the published literature does not contain the kind of controlled dose-finding trials that establish one. What the literature does provide is a route-dependent picture — topical use with a reasonable clinical research base, and injectable use with very little.

This article explains how dose questions differ by route, what variables drive a prescriber's decision, and which safety checks matter regardless of the amount used.

This article is educational and written for licensed prescribers. It is not medical advice, and it does not recommend a dose for any patient.

The Short Answer

• No labeled dose exists. GHK-Cu has no FDA-approved product, and no dose has been established by regulatory review.
• Topical dose is a formulation question. Concentration, vehicle, pH, and complex stability determine what reaches the skin.
• Injectable dose is prescriber-determined and has no controlled dose-finding evidence in the published literature that we are aware of.
• Copper exposure is the safety variable that scales with dose and duration, which is why monitoring matters more than any single number.

GHK-Cu Dosage Depends on the Route

Topical GHK-Cu

Most GHK-Cu use is topical, and this is where the clinical research sits. Studies of GHK-Cu creams have reported improvements in skin density, elasticity, fine-line depth, and photodamage appearance relative to baseline or vehicle. Those studies differed in concentration and vehicle, and effect sizes varied with formulation — which is itself the key dosing lesson. A topical "dose" is inseparable from the formulation it is delivered in.

Practical formulation points that change the effective dose:

• Complex stability. The copper coordination gives GHK-Cu its blue color; loss of that color suggests the complex has degraded and the patient is no longer receiving the characterized molecule.
• Co-applied actives. High-concentration vitamin C and strong chelating agents can destabilize the complex in the formulation. Separating applications by time of day is the usual accommodation.
• Barrier status. Application to freshly disrupted skin after laser or microneedling is a different exposure from application to intact skin; timing relative to a procedure is a clinical decision.

Injectable GHK-Cu

Subcutaneous GHK-Cu preparations exist in compounded practice, but the injectable evidence base is thin. We are not aware of published controlled dose-finding trials for injectable GHK-Cu in humans. Amount, frequency, and course length are therefore prescriber-determined, and they should be reasoned from the patient's goal, copper status, and tolerance rather than from figures circulating online.

The distinguishing concern with systemic routes is cumulative copper. A topical application delivers little systemic copper; repeated injections deliver more, and the relationship between copper and zinc runs in both directions.

Oral, Sublingual, and Nasal Formulations

These formats exist, but absorption is formulation-dependent and the supporting data are minimal. The most frequently reported tolerability issue is a metallic taste, which our GHK-Cu contraindications guide discusses along with practical mitigations.

What Drives a Prescriber's Dosing Decision

Because there is no labeled dose, the decision is built from patient-specific variables:

1. Goal. Skin appearance, post-procedure recovery, and hair applications have different evidence and usually different routes.

1. Route. Topical use keeps systemic copper exposure low; injectable use raises it.
2. Copper and zinc status. Baseline serum copper and zinc are reasonable before chronic systemic use.
3. Liver function. Impaired copper excretion, including advanced liver disease, warrants caution.
4. Concurrent supplements. High-dose zinc competes with copper.
5. Formulation quality. The dose on the label only matters if the complex is intact.

Frequency, Duration, and Monitoring

Course length and frequency are clinical decisions. For chronic or systemic use, the site's safety guidance supports periodic serum copper and zinc, liver function testing on long-duration protocols, and assessment of any new hepatic or neurological symptoms. Monitoring is the practical safeguard that a dose number cannot provide.

Why You'll See Confident Numbers Online

Many GHK-Cu doses quoted online originate with vendors selling "research use only" products or with forum protocols. They are not derived from dose-finding studies, they do not account for formulation differences, and research-use products carry no quality assurance for human use. If a figure has no traceable clinical source, treat it as an assertion rather than evidence.

For reconstitution arithmetic — converting a vial's peptide content and diluent volume into a concentration — use the peptide calculator and our guide on how to reconstitute peptides. Neither recommends a dose.

Questions to Ask the Compounding Partner

Because the formulation largely determines the effective dose, a prescriber considering GHK-Cu can reasonably ask the 503A partner:

• Is this the characterized GHK–copper complex, and what is the source and certificate of analysis for the bulk ingredient?
• What is the concentration and vehicle for topical preparations, and what pH is the formulation held at?
• What beyond-use date applies, and under what storage conditions?
• How is complex stability confirmed in the finished preparation?
• For injectables, what sterility and endotoxin testing is performed?

Clear answers to these questions matter more than any dose figure, because a well-chosen amount of a degraded or uncharacterized product is still the wrong product.

Who Should Not Use GHK-Cu

• Patients with Wilson's disease or unexplained elevated copper
• Patients with a family history of Wilson's disease until it has been excluded
• Pregnancy and lactation — no supporting data
• Caution in advanced liver disease and in patients on significant zinc supplementation

Regulatory Status

As of the site's July 2026 tracker, GHK-Cu was scheduled for Pharmacy Compounding Advisory Committee review before February 2027, with non-injectable routes previously under Category 1 evaluation and injectable routes previously in Category 2. Our GHK-Cu FDA status update explains the dual-route history; the FDA peptide status tracker has the current position.

For the compound itself — structure, mechanisms, and research — see the GHK-Cu peptide page. For the wider picture, visit the peptides for skin hub.

Frequently Asked Questions

What is the standard GHK-Cu dosage?

There is no standard or FDA-labeled GHK-Cu dosage. Topical dose depends on the formulation's concentration and stability, and injectable dose is prescriber-determined because controlled dose-finding trials have not been published.

Is topical or injectable GHK-Cu better?

They serve different purposes and have different evidence. Topical GHK-Cu has the stronger clinical research base for skin appearance; injectable use has very limited human data and raises cumulative copper exposure.

How long does a GHK-Cu course last?

Course length is a clinical decision. Longer or systemic courses are where copper and zinc monitoring becomes most relevant.

Can GHK-Cu be combined with vitamin C?

Not in the same application at high concentrations — vitamin C can destabilize the copper complex in the formulation. Separating applications by time of day is the common approach.

Does GHK-Cu dosage affect zinc levels?

Copper and zinc compete, so higher or chronic systemic exposure makes zinc balance worth monitoring. Short-term topical use has not been prominently associated with clinically significant zinc depletion.